Cytokinetics heart drug scores in closely watched trial
BioPharma Dive
Myqorzo s success in non-obstructive hypertrophic cardiomyopathy separates it from Bristol Myers Squibb s rival Camzyos and opens up a multibillion-dollar market opportunity.
pharminent
May 5, 2026 (Last updated: May 5, 2026)
BioPharma Dive
Myqorzo s success in non-obstructive hypertrophic cardiomyopathy separates it from Bristol Myers Squibb s rival Camzyos and opens up a multibillion-dollar market opportunity.
